Jessica Fye
Stock Analyst at JP Morgan
(4.30)
# 407
Out of 4,966 analysts
200
Total ratings
60.8%
Success rate
12.15%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Overweight | $77 → $78 | $34.73 | +124.59% | 3 | Aug 25, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $48 → $49 | $42.64 | +14.93% | 6 | Aug 25, 2025 | |
| INCY Incyte | Maintains: Neutral | $67 → $73 | $84.61 | -13.72% | 8 | Aug 22, 2025 | |
| INSM Insmed | Maintains: Overweight | $111 → $135 | $136.10 | -0.81% | 9 | Aug 20, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $254 → $260 | $194.27 | +33.83% | 14 | Aug 19, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $60 → $63 | $73.15 | -13.88% | 14 | Aug 7, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $348 → $475 | $446.51 | +6.38% | 8 | Aug 6, 2025 | |
| ONC BeOne Medicines | Maintains: Overweight | $321 → $345 | $306.05 | +12.73% | 3 | Jul 17, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $515 → $517 | $391.02 | +32.22% | 9 | Jul 14, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $108 → $113 | $58.27 | +93.92% | 4 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $330 | $304.76 | +8.28% | 17 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $33 → $26 | $24.09 | +7.93% | 13 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $116 | $100.00 | +16.00% | 12 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $8.31 | +56.44% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $32.22 | +55.18% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $28 | $12.33 | +127.09% | 4 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $209 | $127.75 | +63.60% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $24 | $15.27 | +57.17% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $26 | $28.97 | -10.25% | 6 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $15.09 | +98.81% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $30.99 | +74.25% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $39 | $73.87 | -47.20% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $19.76 | -34.21% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $29.86 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $8.30 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $2.22 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $15.04 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.57 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.57 | +1,301.27% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.10 | +536.36% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $7.32 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $7.47 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.40 | - | 1 | Feb 8, 2018 |
Legend Biotech
Aug 25, 2025
Maintains: Overweight
Price Target: $77 → $78
Current: $34.73
Upside: +124.59%
Ionis Pharmaceuticals
Aug 25, 2025
Maintains: Neutral
Price Target: $48 → $49
Current: $42.64
Upside: +14.93%
Incyte
Aug 22, 2025
Maintains: Neutral
Price Target: $67 → $73
Current: $84.61
Upside: -13.72%
Insmed
Aug 20, 2025
Maintains: Overweight
Price Target: $111 → $135
Current: $136.10
Upside: -0.81%
Ascendis Pharma
Aug 19, 2025
Maintains: Overweight
Price Target: $254 → $260
Current: $194.27
Upside: +33.83%
Halozyme Therapeutics
Aug 7, 2025
Maintains: Neutral
Price Target: $60 → $63
Current: $73.15
Upside: -13.88%
Alnylam Pharmaceuticals
Aug 6, 2025
Maintains: Overweight
Price Target: $348 → $475
Current: $446.51
Upside: +6.38%
BeOne Medicines
Jul 17, 2025
Maintains: Overweight
Price Target: $321 → $345
Current: $306.05
Upside: +12.73%
Vertex Pharmaceuticals
Jul 14, 2025
Maintains: Overweight
Price Target: $515 → $517
Current: $391.02
Upside: +32.22%
BioMarin Pharmaceutical
Jul 14, 2025
Maintains: Overweight
Price Target: $108 → $113
Current: $58.27
Upside: +93.92%
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $304.76
Upside: +8.28%
May 22, 2025
Maintains: Underweight
Price Target: $33 → $26
Current: $24.09
Upside: +7.93%
May 22, 2025
Maintains: Neutral
Price Target: $120 → $116
Current: $100.00
Upside: +16.00%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $8.31
Upside: +56.44%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $32.22
Upside: +55.18%
Apr 10, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $12.33
Upside: +127.09%
Feb 26, 2025
Maintains: Overweight
Price Target: $200 → $209
Current: $127.75
Upside: +63.60%
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $15.27
Upside: +57.17%
Oct 25, 2024
Maintains: Neutral
Price Target: $32 → $26
Current: $28.97
Upside: -10.25%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $15.09
Upside: +98.81%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $30.99
Upside: +74.25%
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $73.87
Upside: -47.20%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $19.76
Upside: -34.21%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $29.86
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $8.30
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $2.22
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $15.04
Upside: -
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.57
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.57
Upside: +1,301.27%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.10
Upside: +536.36%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $7.32
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $7.47
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $8.40
Upside: -